|
ES2327229T3
(es)
|
2002-11-09 |
2009-10-27 |
Immunocore Ltd. |
Presentacion del receptor de linfocitos t.
|
|
RS53984B1
(sr)
|
2003-12-10 |
2015-10-30 |
E. R. Squibb & Sons L.L.C. |
Ip-10 antitela i njihove upotrebe
|
|
CN1889978A
(zh)
|
2003-12-10 |
2007-01-03 |
米德列斯公司 |
干扰素α抗体及其用途
|
|
WO2006002177A2
(en)
|
2004-06-21 |
2006-01-05 |
Medarex, Inc. |
Interferon alpha receptor 1 antibodies and their uses
|
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
MX2007015944A
(es)
|
2005-06-20 |
2008-03-07 |
Medarex Inc |
Anticuerpos cd19 y sus usos.
|
|
PL1907424T3
(pl)
|
2005-07-01 |
2015-12-31 |
Squibb & Sons Llc |
Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1)
|
|
EP2532677A1
(en)
|
2005-10-21 |
2012-12-12 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
|
PL1960434T3
(pl)
|
2005-12-08 |
2012-12-31 |
Squibb & Sons Llc |
Ludzkie przeciwciała monoklonalne przeciw fozylowi-gm1 i sposoby zastosowania antyfukozylu-gm1
|
|
EP2010569A4
(en)
|
2006-03-20 |
2009-09-09 |
Xoma Technology Ltd |
HUMAN ANTIBODIES SPECIFIC TO GASTRINE MATERIALS AND METHODS
|
|
EP2420252A1
(en)
|
2006-08-04 |
2012-02-22 |
Novartis AG |
EPHB3-specific antibody and uses thereof
|
|
EP2046834B9
(en)
|
2006-08-11 |
2013-04-10 |
Ono Pharmaceutical Co., Ltd. |
Monoclonal antibodies against stromal derived factor-1 (sdf-1)
|
|
EA201201533A1
(ru)
|
2006-08-18 |
2014-11-28 |
Новартис Аг |
Prlr-специфическое антитело и его применения
|
|
JP2010502220A
(ja)
|
2006-09-05 |
2010-01-28 |
メダレックス インコーポレーティッド |
骨形態形成タンパク質およびその受容体に対する抗体ならびにその使用方法
|
|
RS54424B1
(sr)
|
2006-10-02 |
2016-04-28 |
E. R. Squibb & Sons, L.L.C. |
Humana antitela koja se vezuju za cxcr4 i njihove upotrebe
|
|
JP2010507365A
(ja)
|
2006-10-19 |
2010-03-11 |
メルク アンド カンパニー インコーポレイテッド |
抗ＩＬ−１３Ｒα１抗体およびその使用
|
|
US8618248B2
(en)
|
2006-10-31 |
2013-12-31 |
President And Fellows Of Harvard College |
Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
|
|
AR063840A1
(es)
|
2006-11-15 |
2009-02-25 |
Medarex Inc |
Anticuerpos humanos monoclonales para btla y metodos de uso
|
|
CA2671457C
(en)
|
2006-12-01 |
2017-09-26 |
Medarex, Inc. |
Human antibodies that bind cd22 and uses thereof
|
|
EA200900767A1
(ru)
|
2006-12-07 |
2009-12-30 |
Новартис Аг |
Антагонистические антитела против ephb3
|
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
|
IN2009KN02404A
(enExample)
|
2006-12-14 |
2015-08-07 |
Medarex Inc |
|
|
ES2537580T3
(es)
|
2007-09-04 |
2015-06-09 |
Compugen Ltd. |
Polipéptidos y polinucleótidos, y usos de los mismos como una diana farmacológica para producir fármacos y agentes biológicos
|
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
|
ES2560532T3
(es)
|
2007-11-02 |
2016-02-19 |
Novartis Ag |
Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6)
|
|
CA3102679A1
(en)
|
2007-12-14 |
2009-06-25 |
Birgitte Urso |
Antibodies against human nkg2d and uses thereof
|
|
CN101970006B
(zh)
|
2008-02-05 |
2014-08-06 |
百时美施贵宝公司 |
α5-β1抗体和它们的用途
|
|
JP5504587B2
(ja)
*
|
2008-05-27 |
2014-05-28 |
東レ株式会社 |
分析用チップ
|
|
EP2328616B1
(en)
|
2008-08-05 |
2015-04-29 |
Novartis AG |
Compositions and methods for antibodies against complement protein c5
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
US20110311450A1
(en)
|
2008-12-08 |
2011-12-22 |
Zurit Levine |
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
|
US8420084B2
(en)
|
2009-03-05 |
2013-04-16 |
Medarex, Inc. |
Fully human antibodies specific to CADM1
|
|
KR20120057563A
(ko)
|
2009-03-31 |
2012-06-05 |
노파르티스 아게 |
Ｉｌ-１２ 수용체 베타ｌ 서부유닛에 대해 특이적인 치료용 항체를 사용하는 조성물 및 방법
|
|
ES2574236T3
(es)
|
2009-04-20 |
2016-06-16 |
Oxford Biotherapeutics Ltd |
Anticuerpos específicos para cadherina-17
|
|
EA201650137A1
(ru)
|
2009-04-27 |
2017-09-29 |
Новартис Аг |
Композиции и способы для усиления мышечного роста
|
|
EP3156485B1
(en)
|
2009-07-17 |
2018-09-12 |
Bioatla, LLC |
Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
|
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
|
CA2772945A1
(en)
|
2009-09-25 |
2011-03-31 |
Xoma Technology Ltd. |
Screening methods
|
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
|
WO2011047083A1
(en)
|
2009-10-13 |
2011-04-21 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
|
WO2011067711A2
(en)
|
2009-12-01 |
2011-06-09 |
Compugen Ltd |
Novel heparanase splice variant
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
NZ602634A
(en)
|
2010-03-26 |
2015-06-26 |
Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
|
MX2012012928A
(es)
|
2010-05-06 |
2013-05-01 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
|
|
EA201291181A1
(ru)
|
2010-05-06 |
2013-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
|
|
CA2803391C
(en)
|
2010-06-22 |
2021-11-09 |
Neogenix Oncology, Inc. |
Npc1 antibodies that bind a muc5ac epitope
|
|
EP2593797B1
(en)
*
|
2010-07-16 |
2019-05-08 |
Bioatla, LLC |
Novel methods of protein evolution
|
|
WO2012021558A1
(en)
|
2010-08-09 |
2012-02-16 |
Richard Markham |
Methods and compositions for preventing a condition
|
|
GEP201706605B
(en)
|
2010-08-20 |
2017-01-25 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
US8999335B2
(en)
|
2010-09-17 |
2015-04-07 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
|
CA2812556C
(en)
|
2010-09-23 |
2023-02-14 |
Xue-Ping Wang |
Colon and pancreas cancer peptidomimetics
|
|
JP2013543384A
(ja)
|
2010-10-05 |
2013-12-05 |
ノバルティス アーゲー |
抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
|
|
JP2014504503A
(ja)
|
2010-12-28 |
2014-02-24 |
ゾーマ テクノロジー リミテッド |
Ｐｄｚドメインを用いた細胞表面提示
|
|
CA2830923A1
(en)
|
2011-04-15 |
2012-10-18 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
|
CN116333113A
(zh)
|
2011-06-03 |
2023-06-27 |
佐马技术有限公司 |
对TGF-β具有特异性的抗体
|
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
|
ES2640960T3
(es)
|
2011-06-28 |
2017-11-07 |
Oxford Biotherapeutics Ltd. |
Anticuerpos para ADP-ribosil ciclasa 2
|
|
CA2836855C
(en)
|
2011-06-30 |
2020-07-14 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
|
SI2726099T1
(sl)
|
2011-07-01 |
2018-11-30 |
Novartis Ag |
Postopek za zdravljenje metaboličnih motenj
|
|
CA2857601A1
(en)
|
2011-12-05 |
2013-06-13 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
|
UY34487A
(es)
|
2011-12-05 |
2013-07-31 |
Novartis Ag |
Anticuerpos para receptor de factor de crecimiento epidérmico 3(her3)
|
|
WO2013093762A1
(en)
|
2011-12-21 |
2013-06-27 |
Novartis Ag |
Compositions and methods for antibodies targeting factor p
|
|
EP2756093A4
(en)
|
2012-02-01 |
2015-07-01 |
Compugen Ltd |
C10RF32 ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER
|
|
AU2013277051B2
(en)
|
2012-06-22 |
2018-06-07 |
King's College London |
Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
CN109793893B
(zh)
|
2012-09-07 |
2023-05-26 |
达特茅斯大学理事会 |
用于诊断和治疗癌症的vista调节剂
|
|
LT2928921T
(lt)
|
2012-12-05 |
2021-04-26 |
Novartis Ag |
Kompozicijos ir būdai, skirti antikūnams nukreipti į epo
|
|
JP2016502850A
(ja)
|
2012-12-18 |
2016-02-01 |
ノバルティス アーゲー |
ヒアルロナンに結合するペプチドタグを使用する組成物及び方法
|
|
EP2938633B1
(en)
|
2012-12-28 |
2018-02-07 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
|
KR101877109B1
(ko)
|
2013-02-08 |
2018-07-10 |
노파르티스 아게 |
항-il-17a 항체 및 자가면역 및 염증성 장애의 치료에서의 그의 용도
|
|
JP2016514130A
(ja)
|
2013-03-14 |
2016-05-19 |
ノバルティス アーゲー |
Ｎｏｔｃｈ３に対する抗体
|
|
US9562101B2
(en)
|
2013-06-21 |
2017-02-07 |
Novartis Ag |
Lectin-like oxidized LDL receptor 1 antibodies and methods of use
|
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
|
KR20160042987A
(ko)
|
2013-08-14 |
2016-04-20 |
노파르티스 아게 |
산발성 봉입체 근염을 치료하는 방법
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
EP4043493A1
(en)
|
2013-12-24 |
2022-08-17 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
|
EP3151921B1
(en)
|
2014-06-06 |
2019-08-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
|
MX389695B
(es)
|
2014-06-11 |
2025-03-20 |
Kathy A Green |
Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
|
|
US20170291939A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
|
US20170290876A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Compositions and methods for long acting proteins
|
|
EP3160991A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
|
AP2017009721A0
(en)
|
2014-08-07 |
2017-01-31 |
Novartis Ag |
Angiopoietin-like 4 antibodies and methods of use
|
|
EP3194437B1
(en)
|
2014-08-07 |
2021-01-20 |
Novartis AG |
Angiopoietin-like 4 (angptl4) antibodies and methods of use
|
|
EP3725808B1
(en)
|
2014-11-21 |
2024-07-17 |
Bristol-Myers Squibb Company |
Antibodies against cd73 and uses thereof
|
|
MX2017007136A
(es)
|
2014-12-05 |
2017-12-04 |
Immunext Inc |
Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
|
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
|
WO2016196228A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Antibodies against ox40 and uses thereof
|
|
CA2982237A1
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
|
|
CA2990360C
(en)
|
2015-06-24 |
2024-02-13 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
|
US11236159B2
(en)
|
2015-08-03 |
2022-02-01 |
Novartis Ag |
Methods of treating FGF21-associated disorders
|
|
US10000561B2
(en)
|
2015-09-09 |
2018-06-19 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
|
|
PE20181368A1
(es)
|
2015-09-09 |
2018-08-27 |
Novartis Ag |
Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas
|
|
EP3377532B1
(en)
|
2015-11-19 |
2022-07-27 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
|
CN109069623A
(zh)
|
2015-12-18 |
2018-12-21 |
诺华股份有限公司 |
靶向CD32b的抗体及其使用方法
|
|
TWI756204B
(zh)
|
2016-02-12 |
2022-03-01 |
比利時商楊森製藥公司 |
抗ｖｉｓｔａ抗體及片段、其用途及鑑定其之方法
|
|
SG11201806861SA
(en)
|
2016-03-04 |
2018-09-27 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
|
UA125382C2
(uk)
|
2016-04-15 |
2022-03-02 |
Імьюнекст Інк. |
Антитіла проти людського vista та їх застосування
|
|
CN109071647B
(zh)
|
2016-04-27 |
2022-11-22 |
诺华股份有限公司 |
抗生长分化因子15的抗体及其用途
|
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
|
CN110381988A
(zh)
|
2016-06-15 |
2019-10-25 |
诺华股份有限公司 |
使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法
|
|
TW202244061A
(zh)
|
2016-07-14 |
2022-11-16 |
美商必治妥美雅史谷比公司 |
針對tim3之抗體及其用途
|
|
EP3494141A4
(en)
|
2016-08-03 |
2020-04-08 |
Bio-Techne Corporation |
Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
|
|
US11332521B2
(en)
|
2016-11-07 |
2022-05-17 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
|
US11339209B2
(en)
|
2016-11-14 |
2022-05-24 |
Novartis Ag |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
|
CN110325550B
(zh)
|
2016-12-23 |
2024-03-08 |
诺华股份有限公司 |
因子xi抗体和使用方法
|
|
AU2017386682A1
(en)
|
2016-12-28 |
2019-07-25 |
Invvax, Inc. |
Influenza vaccines
|
|
US10899844B2
(en)
|
2017-02-08 |
2021-01-26 |
Novartis Ag |
FGF21 mimetic antibodies and uses thereof
|
|
WO2018175460A1
(en)
|
2017-03-24 |
2018-09-27 |
Novartis Ag |
Methods for preventing and treating heart disease
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
KR102574549B1
(ko)
|
2017-06-27 |
2023-09-07 |
주식회사 뉴라클사이언스 |
항-fam19a5 항체 및 이의 용도
|
|
WO2019003104A1
(en)
|
2017-06-28 |
2019-01-03 |
Novartis Ag |
METHOD FOR PREVENTING AND TREATING URINARY INCONTINENCE
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
WO2019102353A1
(en)
|
2017-11-22 |
2019-05-31 |
Novartis Ag |
Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
|
|
CN111886255B
(zh)
|
2018-01-12 |
2025-04-04 |
百时美施贵宝公司 |
抗tim3抗体及其用途
|
|
CN111868082A
(zh)
|
2018-02-02 |
2020-10-30 |
博奥泰克尼公司 |
调节vista和vsig3的相互作用的化合物及其制备和使用方法
|
|
KR102761890B1
(ko)
|
2018-03-23 |
2025-02-06 |
브리스톨-마이어스 스큅 컴퍼니 |
Mica 및/또는 micb에 대한 항체 및 그의 용도
|
|
TW202513581A
(zh)
|
2018-03-28 |
2025-04-01 |
美商必治妥美雅史谷比公司 |
介白素-2/介白素-2受體阿法融合蛋白及其使用方法
|
|
EP3790898A4
(en)
|
2018-05-10 |
2022-03-02 |
Neuracle Science Co., Ltd |
SEQUENCE-LIKE ANTI-FAMILY ANTIBODIES 19, MEMBER A5, AND METHOD OF USE THEREOF
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
WO2020131935A1
(en)
|
2018-12-18 |
2020-06-25 |
Novartis Ag |
Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
|
|
US12247075B2
(en)
|
2018-12-26 |
2025-03-11 |
Imcheck Therapeutics Sas |
BTN3A binding proteins and uses thereof
|
|
WO2020141452A1
(en)
|
2019-01-02 |
2020-07-09 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
|
KR102570405B1
(ko)
|
2019-01-22 |
2023-08-25 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
PE20231093A1
(es)
|
2020-07-16 |
2023-07-18 |
Novartis Ag |
Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas
|
|
US12018254B2
(en)
*
|
2020-07-27 |
2024-06-25 |
Wisconsin Alumni Research Foundation |
Methods of making unbiased phage libraries
|
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
TW202400638A
(zh)
|
2022-05-10 |
2024-01-01 |
法商感應檢查療法公司 |
用於治療胃腸發炎病症之方法的抗btn3a抗體
|
|
WO2025155877A2
(en)
|
2024-01-18 |
2025-07-24 |
The Regents Of The University Of California |
Antibodies binding to pad4 and uses thereof
|